Aldosterone and cardiovascular diseases
Cardiovascular Research · 17.03.2023 · 119 (1) · 28-44
DOI: 10.1093/cvr/cvac027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 07.04.2022. Verfasst von Wasita W Parksook und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Atrial Fibrillation, Heart Failure, Hypertension. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 200 Literaturangaben.
Abstract (Originalsprache)
Aldosterone’s role in the kidney and its pathophysiologic actions in hypertension are well known. However, its role or that of its receptor [minieralocorticoid receptor (MR)] in other cardiovascular (CV) disease are less well described. To identify their potential roles in six CV conditions (heart failure, myocardial infarction, atrial fibrillation, stroke, atherosclerosis, and thrombosis), we assessed these associations in the following four areas: (i) mechanistic studies in rodents and humans; (ii) pre-clinical studies of MR antagonists; (iii) clinical trials of MR antagonists; and (iv) genetics. The data were acquired from an online search of the National Library of Medicine using the PubMed search engine from January 2011 through June 2021. There were 3702 publications identified with 200 publications meeting our inclusion and exclusion criteria. Data strongly supported an association between heart failure and dysregulated aldosterone/MR. This association is not surprising given aldosterone/MR’s prominent role in regulating sodium/volume homeostasis. Atrial fibrillation and myocardial infarction are also associated with dysregulated aldosterone/MR, but less strongly. For the most part, the data were insufficient to determine whether there was a relationship between atherosclerosis, stroke, or thrombosis and aldosterone/MR dysregulation. This review clearly documented an expanding role for aldosterone/MR’s dysregulation in CV diseases beyond hypertension. How expansive it might be is limited by the currently available data. It is anticipated that with an increased focus on aldosterone/MR’s potential roles in these diseases, additional clinical and pre-clinical data will clarify these relationships, thereby, opening approaches to use modulators of aldosterone/MR’s action to more precisely treat these CV conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Endocrinology and Metabolism, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
- Division of General Internal Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
ORCID-Profile: Wasita W Parksook
Zitieren
APA
Parksook, W. W., & Williams, G. H. (2023). Aldosterone and cardiovascular diseases. Cardiovascular Research, 119(1), 28-44. https://doi.org/10.1093/cvr/cvac027
Vancouver
Parksook WW, Williams GH. Aldosterone and cardiovascular diseases. Cardiovascular Research. 2023;119(1):28-44. doi:10.1093/cvr/cvac027
BibTeX
@article{Parksook2023,
author = {Parksook, Wasita W and Williams, Gordon H},
title = {Aldosterone and cardiovascular diseases},
journal = {Cardiovascular Research},
year = {2023},
volume = {119},
number = {1},
pages = {28--44},
doi = {10.1093/cvr/cvac027}
}
EUVIMED